Contact Dermatitis-Pipeline Review, H1 2017

Contact Dermatitis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9173IDB
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Contact Dermatitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis-Pipeline Review, H1 2017, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively.

Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Contact Dermatitis-Overview

Contact Dermatitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Contact Dermatitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Contact Dermatitis-Companies Involved in Therapeutics Development

Anacor Pharmaceuticals Inc

AskAt Inc

Brickell Biotech Inc

Dr. August Wolff GmbH & Co KG Arzneimittle

Edesa Biotech Inc

Hapten Sciences Inc

ILiAD Biotechnologies LLC

Marinomed Biotechnologie GmbH

Novartis AG

Signum Dermalogix Inc

Contact Dermatitis-Drug Profiles

AAT-008-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-3485-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-2000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beta-escin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

grapiprant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPT-721-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

secukinumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIG-1322-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WOL-071007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Contact Dermatitis-Dormant Projects

Contact Dermatitis-Discontinued Products

Contact Dermatitis-Product Development Milestones

Featured News & Press Releases

Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Contact Dermatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Contact Dermatitis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Contact Dermatitis-Pipeline by Anacor Pharmaceuticals Inc, H1 2017

Contact Dermatitis-Pipeline by AskAt Inc, H1 2017

Contact Dermatitis-Pipeline by Brickell Biotech Inc, H1 2017

Contact Dermatitis-Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017

Contact Dermatitis-Pipeline by Edesa Biotech Inc, H1 2017

Contact Dermatitis-Pipeline by Hapten Sciences Inc, H1 2017

Contact Dermatitis-Pipeline by ILiAD Biotechnologies LLC, H1 2017

Contact Dermatitis-Pipeline by Marinomed Biotechnologie GmbH, H1 2017

Contact Dermatitis-Pipeline by Novartis AG, H1 2017

Contact Dermatitis-Pipeline by Signum Dermalogix Inc, H1 2017

Contact Dermatitis-Dormant Projects, H1 2017

Contact Dermatitis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anacor Pharmaceuticals Inc, AskAt Inc, Brickell Biotech Inc, Dr. August Wolff GmbH & Co KG Arzneimittle, Edesa Biotech Inc, Hapten Sciences Inc, ILiAD Biotechnologies LLC, Marinomed Biotechnologie GmbH, Novartis AG, Signum Dermalogix Inc

select a license

Single User License
USD 2000 INR 128160
Site License
USD 4000 INR 256320
Corporate User License
USD 6000 INR 384480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com